Today: 2 July 2026
Broadcom stock price forecast: AVGO tests $350 after $4.5B bond pricing and Wi‑Fi 8 launch
7 January 2026
2 mins read

Broadcom stock price forecast: AVGO tests $350 after $4.5B bond pricing and Wi‑Fi 8 launch

New York, Jan 7, 2026, 14:36 EST — Regular session

  • Broadcom shares moved higher after the company priced a four-part senior notes sale aimed at debt repayment.
  • Broadcom rolled out new Wi‑Fi 8 chips, pitching more AI tasks running on-device in home networks.
  • Traders are mapping mid-$340s support and a possible $350 retest ahead of the next earnings update.

Broadcom shares rose 0.9% to $346.8 on Wednesday after a pricing term sheet showed the chipmaker locked in terms for a $4.5 billion, four-part senior notes sale. Coupons run from 4.3% due 2031 to 5.7% due 2056, with spreads of 60 to 88 basis points — 0.60 to 0.88 percentage point — over Treasuries. Broadcom estimated net proceeds of about $4.47 billion and said it plans to use the money for general corporate purposes and debt repayment, with closing set for Jan. 13.

The funding move matters for AVGO because the stock still trades like a rates-and-growth name, not a slow-and-steady chipmaker. The Broadcom stock price forecast has become as much about financing costs and margin durability as it is about demand for silicon.

The debt print also lands at an awkward moment in the AI trade, when investors are trying to separate “more chips sold” from “more profit kept.” Bond pricing rarely drives a semiconductor stock by itself, but it can sharpen the debate about how much room a company has to keep investing, buying, and refinancing without surprises.

In the broader tape, tech held up better than the chip group. The Invesco QQQ was up about 0.4%, while the iShares Semiconductor ETF fell roughly 1.2% and the SPDR S&P 500 ETF was little changed.

Broadcom on Tuesday launched its BCM4918 accelerated processing unit, or APU, and two dual-band Wi‑Fi 8 chips, the BCM6714 and BCM6719, aiming to support real-time AI applications in home gateways and routers. “Wi‑Fi 8 represents a turning point for the industry—where broadband, connectivity, compute, and intelligence truly converge,” said Mark Gonikberg, a senior vice president at Broadcom. Nasdaq

On charts, traders are treating the mid-$340s as the near-term line in the sand. Investing.com pegged Broadcom’s 50-day moving average at $347.37 and its 200-day at $364.39, with near-term pivot resistance clustered around $347–$349.

But Wi‑Fi 8 is still a draft standard, and the final IEEE specification is not expected until 2028, which can complicate early product cycles. The Verge said first-wave gear may rely on draft specs and could need firmware updates as the standard firms up, with rivals such as MediaTek also flagging early silicon at CES.

Broadcom’s last earnings report in December showed revenue of $18.0 billion for the fourth quarter, and CEO Hock Tan said AI semiconductor revenue increased 74% from a year earlier. The company guided for about $19.1 billion of first-quarter revenue and said adjusted EBITDA — a profit measure — should run at 67% of revenue.

Next up is Broadcom’s first-quarter fiscal 2026 earnings report, which the company said it currently plans to release after the market closes on March 4, followed by a webcast at 2 p.m. Pacific. Investors will be listening for any change in the AI demand outlook and for how management frames margins as AI mix rises.

Marcin Frąckiewicz is the founder and CEO of TS2 Space, a satellite communications company serving customers around the world. A graduate of the Warsaw School of Economics (SGH), he has more than two decades of experience in telecommunications, satellite services and technology ventures. He writes about satellite communications, space technology, artificial intelligence and the stock market, with a particular focus on technology companies, semiconductors, emerging industries and the trends shaping global innovation.

Stock Market Today

  • SPDR S&P Biotech ETF (XBI) draws $591M as shares climb
    July 2, 2026, 11:58 AM EDT. The SPDR S&P Biotech ETF (XBI) pulled in about $591 million in inflows this week, lifting outstanding units by 5.8% from 65.3 million to 69.1 million. Shares last traded at $159.31, just below the 52-week high of $160.82, and up sharply from the low of $83.02. Top holdings include Apogee Therapeutics (APGE), which was flat, Kymera Therapeutics (KYMR) up 0.6%, and Twist Bioscience (TWST) up 1.2%. ETFs use units, and swings in shares outstanding track demand as investors pile in. The buying shows traders are targeting biotech exposure through XBI.
Gold price slips, GLD stock falls as traders brace for Friday’s U.S. jobs report
Previous Story

Gold price slips, GLD stock falls as traders brace for Friday’s U.S. jobs report

SpaceX lines up back-to-back Starlink launches from Florida as orbit crowding comes into focus
Next Story

SpaceX lines up back-to-back Starlink launches from Florida as orbit crowding comes into focus

Go toTop